Literature DB >> 1998995

Instability of the anticancer agent etoposide under in vitro culture conditions.

R M Mader1, G G Steger, K Moser, H Rainer, P Krenmayr, C Dittrich.   

Abstract

Degradation of etoposide is rapid under in vitro culture conditions. At pH 7.4 and 37 degrees C, the isomerisation of trans-etoposide to the inactive compound cis-etoposide has a half-life of 2 days in Dulbecco's modified Eagle's medium and results in the loss of 90% of the active drug within 1 week. As a consequence, prolonged incubations with etoposide in in vitro assays may lead to erroneous interpretations ignoring the real in vitro situation. The degradation is not influenced by organic compounds such as bovine serum albumin or amino acids but depends strongly on the pH value and, to a lesser degree, on the ionic strength of the medium. Therefore, we propose a mathematical correction based on the pH value so as to obtain the real exposure of cells to trans-etoposide during in vitro assays.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998995     DOI: 10.1007/bf00688857

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies.

Authors:  A Gouyette; A Deniel; J L Pico; J P Droz; D Baume; M Ostronoff; N le Bail; M Hayat
Journal:  Eur J Cancer Clin Oncol       Date:  1987-11

2.  Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.

Authors:  P M Politi; B K Sinha
Journal:  Mol Pharmacol       Date:  1989-03       Impact factor: 4.436

3.  High-performance liquid chromatography of etoposide in plasma and urine.

Authors:  V J Harvey; S P Joel; A Johnston; M L Slevin
Journal:  J Chromatogr       Date:  1985-05-03

4.  Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity.

Authors:  E J Pavlik; D E Kenady; J R van Nagell; K Keaton; M B Hanson; E S Donaldson; W O Griffen; R C Flanigan
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.

Authors:  R J Strife; I Jardine; M Colvin
Journal:  J Chromatogr       Date:  1980-05-09

6.  Chemical and biological stability of anticancer drugs used in a human tumor clonogenic assay.

Authors:  R Ludwig; D S Alberts
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.

Authors:  W E Evans; J A Sinkule; W R Crom; L Dow; A T Look; G Rivera
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale?

Authors:  L M Allen; F Tejada; A D Okonmah; S Nordqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Stability-indicating liquid chromatographic determination of etoposide and benzyl alcohol in injectable formulations.

Authors:  B J Floor; A E Klein; N Muhammad; D Ross
Journal:  J Pharm Sci       Date:  1985-02       Impact factor: 3.534

10.  Pharmacokinetics of high dose etoposide (VP 16-213).

Authors:  J J Holthuis; P E Postmus; W J Van Oort; B Hulshoff; H Verleun; D T Sleijfer; N H Mulder
Journal:  Eur J Cancer Clin Oncol       Date:  1986-10
View more
  1 in total

1.  Preferential induction of MLL(Mixed Lineage Leukemia) rearrangements in human lymphocyte cultures treated with etoposide.

Authors:  María Sol Brassesco; Ana Paula Montaldi; Elza Tiemi Sakamoto-Hojo
Journal:  Genet Mol Biol       Date:  2009-03-01       Impact factor: 1.771

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.